How many insider trades does FilingIQ track for LXRX?

FilingIQ tracks 625 Form 4 insider transactions for LXRX (LEXICON PHARMACEUTICALS, INC.), covering filings from Apr 24, 2015 onwards. 66 of those were filed in the last 90 days.

Are LXRX insiders net buyers or net sellers?

Across the full Form 4 history for LXRX, 210 transactions (34%) were open-market purchases and 5 (1%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does LXRX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is LXRX in?

LEXICON PHARMACEUTICALS, INC. (LXRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $653.96M.

LXRX insider trading

NasdaqCM Healthcare

LEXICON PHARMACEUTICALS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

625

Last 90 days

Buys / sells

34% / 1%

Market cap

$653.96M

About LEXICON PHARMACEUTICALS, INC.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Company website: www.lexpharma.com

LXRX insider activity at a glance

FilingIQ has scored 625 insider transactions for LXRX since Apr 24, 2015. The most recent filing in our index is dated May 1, 2026.

Across the full history, 210 open-market purchases and 5 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on LXRX insider trades is 47.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live LXRX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding LXRX

Artal Group S.A.

$273.69M · 7.0% of AUM

Siren, L.L.C.

$17.93M · 1.0% of AUM

Frequently asked

How many insider trades does FilingIQ track for LXRX?: FilingIQ tracks 625 Form 4 insider transactions for LXRX (LEXICON PHARMACEUTICALS, INC.), covering filings from Apr 24, 2015 onwards. 66 of those were filed in the last 90 days.
Are LXRX insiders net buyers or net sellers?: Across the full Form 4 history for LXRX, 210 transactions (34%) were open-market purchases and 5 (1%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does LXRX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is LXRX in?: LEXICON PHARMACEUTICALS, INC. (LXRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $653.96M.

Methodology & sources

Every LXRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.